Director · ENANTA PHARMACEUTICALS INC · ENANTA PHARMACEUTICALS INC — Stock Option (right to buy)
Side
A
Value
—
Shares
20.0K
Price
—
Executed
Mar 11, 2026
Disclosed
Mar 13, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Mar 11 executedMar 13, 2026 disclosed
ENTA · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Grant or award — administrative, little informational value
Relative size+1 / 25
No reported dollar value · new position
Filing timing0 / 15
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
ENANTA PHARMACEUTICALS INC — Stock Option (right to buy)
Ticker
ENTA
Shares
20.0K
Price per share
$0
Execution date (reported)
Mar 11, 2026
Owned after transaction
20.0K shares
Days from execution to publication
2
What this establishes
Foletta Mark G filed this Form 4 reporting a grant or award of ENTA on Mar 11, 2026. It became public on Mar 13, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Director
Foletta Mark Gcik:0001236389
Issuer
ENANTA PHARMACEUTICALS INCcik:0001177648
Revision history · 0
No field has changed since this record was first ingested.
